Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey.
Rega Institute for Medical Research, KU Leuven, Department of Microbiology, Immunology and Transplantation, B-3000 Leuven, Belgium.
Bioorg Med Chem. 2020 Jan 1;28(1):115130. doi: 10.1016/j.bmc.2019.115130. Epub 2019 Nov 8.
The influenza virus hemagglutinin (HA) mediates membrane fusion after viral entry by endocytosis. The fusion process requires drastic low pH-induced HA refolding and is prevented by arbidol and tert-butylhydroquinone (TBHQ). We here report a class of superior inhibitors with indole-substituted spirothiazolidinone structure. The most active analogue 5f has an EC value against influenza A/H3N2 virus of 1 nM and selectivity index of almost 2000. Resistance data and in silico modeling indicate that 5f combines optimized fitting in the TBHQ/arbidol HA binding pocket with a capability for endosomal accumulation. Both criteria appear relevant to achieve superior inhibitors of HA-mediated fusion.
流感病毒血凝素(HA)通过内吞作用介导病毒进入后的膜融合。融合过程需要剧烈的低 pH 诱导的 HA 重折叠,而利巴韦林和叔丁基对苯二酚(TBHQ)可以阻止这一过程。我们在这里报告了一类具有吲哚取代螺噁唑烷酮结构的优秀抑制剂。最活跃的类似物 5f 对甲型流感病毒/H3N2 的 EC 值为 1 nM,选择性指数接近 2000。耐药数据和计算机模拟表明,5f 结合了在 TBHQ/利巴韦林 HA 结合口袋中的优化适配,以及内体积累的能力。这两个标准似乎都与实现 HA 介导的融合的优秀抑制剂有关。